Biofrontera Inc(纳斯达克代码:BFRI)近日宣布,其针对躯干及四肢光化性角化病的Ameluz®药物一期药代动力学研究已完成数据库锁定。这一关键步骤标志着该临床试验数据收集阶段的正式结束,为后续的数据分析和结果评估奠定了坚实基础。公司表示,此项研究的推进将进一步丰富Ameluz®在皮肤疾病治疗领域的临床应用数据。
Biofrontera Inc(纳斯达克代码:BFRI)近日宣布,其针对躯干及四肢光化性角化病的Ameluz®药物一期药代动力学研究已完成数据库锁定。这一关键步骤标志着该临床试验数据收集阶段的正式结束,为后续的数据分析和结果评估奠定了坚实基础。公司表示,此项研究的推进将进一步丰富Ameluz®在皮肤疾病治疗领域的临床应用数据。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.